Immatics is a clinical-stage biopharmaceutical company developing T-cell receptor (TCR) based immunotherapies against solid tumors. Its platforms identify tumor-associated peptide targets and engineer TCR-T cells and TCR bispecifics designed to recognize antigens presented on cancer cells. The company partners with larger pharma while advancing proprietary programs for patients with limited options in hard-to-treat cancers.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 4.7 | — | -70.3 | — |
| Q3 2025 | 5.2 | — | -50.5 | — |
| Q4 2025 | 19.8 | — | -35.7 | — |
| Q1 2026 | 7.6 | — | -57.8 | — |
| Q2 2026 | 9.1 | 93% | -62.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Critical Metals Corp. (CRML), Replimune Group, Inc. (REPL), Harrow, Inc. (HROW), Oaktree Specialty Lending Corporation (OCSL), Business First Bancshares, Inc. (BFST), Green Plains Inc. (GPRE)